$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000162828019010478 Filed on August 08, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$18.00K	$18.00K	$18.00K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.570M	$2.850M	$3.350M
YoY Change	-14.05%	-14.93%	-52.55%
% of Gross Profit
Research & Development	$2.440M	$1.836M	$10.01M
YoY Change	-64.53%	-81.66%	-29.87%
% of Gross Profit
Depreciation & Amortization	$130.0K	$170.0K	$560.0K
YoY Change	-76.36%	-69.64%	-15.15%
% of Gross Profit
Operating Expenses	$5.011M	$4.686M	$13.36M
YoY Change	-49.24%	-64.93%	-37.37%
Operating Profit	-$4.993M	-$4.668M	-$13.34M
YoY Change	-49.33%	-65.02%	-37.4%
Interest Expense	$517.0K	$538.0K	$621.0K
YoY Change	-16.61%	-13.37%	2.99%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.423M	-$5.015M	-$13.85M
YoY Change	-47.21%	-63.78%	-36.29%
Income Tax	$0.00	$1.000K	$0.00
% Of Pretax Income
Net Earnings	-$5.423M	-$5.016M	-$13.85M
YoY Change	-47.21%	-63.78%	-35.92%
Net Earnings / Revenue	-30127.78%	-27866.67%	-76927.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$260.0K	-$300.4K	-$1.594M
COMMON SHARES
Basic Shares Outstanding	20.82M shares	20.55M shares	104.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.60M	$19.60M	$32.90M
YoY Change	-28.78%	-40.43%	-17.96%
Cash & Equivalents	$14.65M	$19.57M	$13.49M
Short-Term Investments			$19.40M
Other Short-Term Assets	$358.0K	$556.0K	$1.536M
YoY Change	-50.07%	-63.8%	-49.11%
Inventory
Prepaid Expenses	$3.826M	$3.826M	$4.655M
Receivables	$700.0K	$300.0K	$200.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.53M	$24.28M	$39.23M
YoY Change	-23.24%	-38.1%	-21.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.042M	$974.0K	$8.906M
YoY Change	-87.48%	-89.06%	-17.18%
Goodwill
YoY Change
Intangibles	$303.0K	$406.0K	$705.0K
YoY Change	-55.18%	-42.41%	-14.34%
Long-Term Investments
YoY Change
Other Assets	$536.0K	$27.00K	$328.0K
YoY Change	63.91%	-91.77%	-3.53%
Total Long-Term Assets	$1.881M	$1.407M	$9.939M
YoY Change	-79.83%	-85.84%	-16.59%
TOTAL ASSETS
Total Short-Term Assets	$19.53M	$24.28M	$39.23M
Total Long-Term Assets	$1.881M	$1.407M	$9.939M
Total Assets	$21.41M	$25.69M	$49.17M
YoY Change	-38.42%	-47.75%	-20.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.521M	$1.602M	$5.468M
YoY Change	23.16%	-70.7%	11.57%
Accrued Expenses	$1.212M	$1.152M	$2.090M
YoY Change	-34.7%	-44.88%	-55.69%
Deferred Revenue	$24.00K	$42.00K
YoY Change	-66.67%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.90M	$14.90M	$19.90M
YoY Change	-21.99%	-25.13%
Total Short-Term Liabilities	$21.00M	$20.49M	$30.80M
YoY Change	-18.13%	-33.48%	176.89%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$200.0K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$549.0K	$461.0K	$437.0K
YoY Change	47.18%	5.49%	54.42%
Total Long-Term Liabilities	$549.0K	$461.0K	$437.0K
YoY Change	47.18%	5.49%	54.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.00M	$20.49M	$30.80M
Total Long-Term Liabilities	$549.0K	$461.0K	$437.0K
Total Liabilities	$21.55M	$20.95M	$38.74M
YoY Change	-35.06%	-45.92%	-7.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$406.4M	-$401.0M	-$373.9M
YoY Change	5.79%	7.25%	18.48%
Common Stock	$406.3M	$405.7M	$384.4M
YoY Change	5.31%	5.55%	14.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$143.0K	$4.743M	$10.43M
YoY Change
Total Liabilities & Shareholders Equity	$21.41M	$25.69M	$49.17M
YoY Change	-38.42%	-47.75%	-20.51%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$5.423M	-$5.016M	-$13.85M
YoY Change	-47.21%	-63.78%	-35.92%
Depreciation, Depletion And Amortization	$130.0K	$170.0K	$560.0K
YoY Change	-76.36%	-69.64%	-15.15%
Cash From Operating Activities	-$4.720M	-$5.690M	-$12.21M
YoY Change	-58.78%	-53.4%	-29.54%
INVESTING ACTIVITIES
Capital Expenditures	-$160.0K		$0.00
YoY Change	700.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$30.00K	$110.0K	$15.71M
YoY Change	-99.77%	-99.3%	5.01%
Cash From Investing Activities	-$140.0K	$110.0K	$15.71M
YoY Change	-101.08%	-99.3%	4.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-70.00K	14.83M	-70.00K
YoY Change	-92.13%	-21285.71%
NET CHANGE
Cash From Operating Activities	-4.720M	-5.690M	-12.21M
Cash From Investing Activities	-140.0K	110.0K	15.71M
Cash From Financing Activities	-70.00K	14.83M	-70.00K
Net Change In Cash	-4.930M	9.250M	3.430M
YoY Change	-935.59%	169.68%	-245.96%
FREE CASH FLOW
Cash From Operating Activities	-$4.720M	-$5.690M	-$12.21M
Capital Expenditures	-$160.0K		$0.00
Free Cash Flow	-$4.560M		-$12.21M
YoY Change	-60.1%		-29.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20824638	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q2	dei	Entity Number Of Employees EntityNumberOfEmployees	21	employee
	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
CY2018Q1	rgls	Accumulated Other Comprehensive Income Loss Unrealized Gainon Short Term Investments AccumulatedOtherComprehensiveIncomeLossUnrealizedGainonShortTermInvestments	7000	USD
CY2018Q2	rgls	Accumulated Other Comprehensive Income Loss Unrealized Gainon Short Term Investments AccumulatedOtherComprehensiveIncomeLossUnrealizedGainonShortTermInvestments	47000	USD
CY2019Q2	rgls	Cashand Cash Equivalentsand Marketable Securities CashandCashEquivalentsandMarketableSecurities	19600000	USD
CY2019Q2	rgls	Finance Lease Liability Payments Due Noncurrent FinanceLeaseLiabilityPaymentsDueNoncurrent	196000	USD
CY2019Q2	rgls	Finance Lease Liability Undiscounted Excess Amount Current FinanceLeaseLiabilityUndiscountedExcessAmountCurrent	270000	USD
	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	0	USD
	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	1839000	USD
CY2019Q2	rgls	Lease Liabilities LeaseLiabilities	487000	USD
CY2019Q1	rgls	Lease Payments Eliminated LeasePaymentsEliminated	14400000	USD
CY2019Q2	rgls	Lease Payments Eliminated LeasePaymentsEliminated	4800000	USD
CY2019Q2	rgls	Lease Right Of Use Asset LeaseRightOfUseAsset	557000	USD
	rgls	Noncash Gain Dueto Reductionof Lease Liability NoncashGainDuetoReductionofLeaseLiability	1300000	USD
	rgls	Noncash Leasehold Improvements NoncashLeaseholdImprovements	5600000	USD
CY2018Q4	rgls	Numberof Optionholders NumberofOptionholders	31	optionholder
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2019Q2	rgls	Operatingand Finance Lease Payments OperatingandFinanceLeasePayments	71000	USD
	rgls	Operatingand Finance Lease Payments OperatingandFinanceLeasePayments	794000	USD
	rgls	Payments For Finance Leases PaymentsForFinanceLeases	-417000	USD
	rgls	Payments For Finance Leases PaymentsForFinanceLeases	130000	USD
CY2018Q4	rgls	Rent Less Current Portion Liability RentLessCurrentPortionLiability	6820000	USD
CY2016Q4	rgls	Tenant Improvement Allowance TenantImprovementAllowance	8200000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1357000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	959000	USD
CY2019Q2	rgls	Rent Less Current Portion Liability RentLessCurrentPortionLiability	0	USD
CY2018Q4	rgls	Share Based Eligible Exchange Offer Shares ShareBasedEligibleExchangeOfferShares	915009	shares
CY2019Q2	rgls	Stock Issued During Period Shares Preferred Stock Warants From Private Placement Netof Offering Costs Value StockIssuedDuringPeriodSharesPreferredStockWarantsFromPrivatePlacementNetofOfferingCostsValue	15505000	USD
CY2018Q4	rgls	Upfront Payment Received UpfrontPaymentReceived	2500000	USD
CY2019Q1	rgls	Upfront Payment Received UpfrontPaymentReceived	1800000	USD
CY2018Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	26000	USD
CY2019Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	331000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1714000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1602000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-87000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1625000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1152000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	386860000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	405721000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1627000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	321000	USD
CY2018Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	400000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1357000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2984000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	319000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1278000	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	512108	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	562659	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2467966	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1240801	shares
CY2018Q4	us-gaap	Assets Assets	27927000	USD
CY2019Q2	us-gaap	Assets Assets	25691000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	19295000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	24284000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	11173000	USD
CY2019Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	16284000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13519000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13485000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13935000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19571000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-34000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5636000	USD
CY2019Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1375000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-772000	USD
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8818019	shares
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-231000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-883000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	21000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-174000	USD
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20824388	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8818019	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20824388	shares
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13800000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29819000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5016000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8276000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2572000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	42000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1843000	USD
CY2018Q4	us-gaap	Debt Current DebtCurrent	16575000	USD
CY2019Q2	us-gaap	Debt Current DebtCurrent	14621000	USD
CY2019Q2	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	900000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1121000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	673000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.59
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.44
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1601000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	829000	USD
CY2019Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	13000	USD
CY2019Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	6000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	13000	USD
CY2019Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	466000	USD
CY2019Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	600000	USD
CY2019Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	287000	USD
CY2019Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	200000	USD
CY2019Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	487000	USD
CY2019Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	57000	USD
CY2019Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	287000	USD
CY2019Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	143000	USD
CY2019Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	21000	USD
CY2019Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	130000	USD
CY2019Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	557000	USD
CY2019Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	600000	USD
CY2019Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	46000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	91000	USD
CY2019Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049
CY2019Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-1600000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3349000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7122000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2850000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6383000	USD
CY2015Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	1400000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13847000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29872000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5015000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8275000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-189000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	305000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-276000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-112000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-927000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-478000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-36000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2536000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-613000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-761000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2837000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-128000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-368000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	500000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	406000	USD
CY2018Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	118000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	282000	USD
CY2019Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	191000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	205000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	621000	USD
	us-gaap	Interest Expense InterestExpense	1227000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	538000	USD
	us-gaap	Interest Expense InterestExpense	1074000	USD
	us-gaap	Interest Paid InterestPaid	1045000	USD
	us-gaap	Interest Paid InterestPaid	854000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	301000	USD
	us-gaap	Lease Cost LeaseCost	679000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4800000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4800000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	600000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1200000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1200000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1200000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2984000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1278000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	600000	USD
CY2015Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P96M
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P51M
CY2018Q4	us-gaap	Liabilities Liabilities	33781000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	20948000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27927000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25691000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26646000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20487000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	626000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15486000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27151000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	274000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27811000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10124000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-16025000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-13847000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29873000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3260000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-5016000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8276000	USD
CY2015Q3	us-gaap	Net Rentable Area NetRentableArea	59248	sqft
CY2019Q1	us-gaap	Net Rentable Area NetRentableArea	24562	sqft
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	306000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	6000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	13362000	USD
	us-gaap	Operating Expenses OperatingExpenses	28963000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	4686000	USD
	us-gaap	Operating Expenses OperatingExpenses	14202000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13344000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28927000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4668000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7406000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	249000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	575000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11300000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	651000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.000
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1140000	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	556000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	326000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	47000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	54000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2559000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2241000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	309000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	461000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	109000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	151000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	415898	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	415898	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	415898	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	415898	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	415898	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	415898	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4194000	USD
CY2019Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3826000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	208000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2086000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	15505000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	27151000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	282000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7806000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	974000	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1977000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10013000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21841000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1836000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7819000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-392723000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400999000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	306000	shares
CY2018Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	603058	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8681311	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6796000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-5854000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-6069000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	4743000	USD
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8693788	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	207000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2084000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	35216000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	22876000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	10433000	USD
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16705587	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13560183	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-010478-index-headers.html	Edgar Link	pending
0001628280-19-010478-index.html	Edgar Link	pending
0001628280-19-010478.txt	Edgar Link	pending
0001628280-19-010478-xbrl.zip	Edgar Link	pending
ex-104x20190630.htm	Edgar Link	pending
ex-105x20190630.htm	Edgar Link	pending
ex-106x20190630.htm	Edgar Link	pending
ex-107x20190630.htm	Edgar Link	pending
ex-311x20190630.htm	Edgar Link	pending
ex-321x20190630.htm	Edgar Link	pending
ex104a.jpg	Edgar Link	pending
ex104a1a03.jpg	Edgar Link	pending
ex104b.jpg	Edgar Link	pending
ex104c.jpg	Edgar Link	pending
ex104g.jpg	Edgar Link	pending
ex104h.jpg	Edgar Link	pending
ex105a01.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20190630.xml	Edgar Link	completed
rgls-20190630.xsd	Edgar Link	pending
rgls-20190630_cal.xml	Edgar Link	unprocessable
rgls-20190630_def.xml	Edgar Link	unprocessable
rgls-20190630_lab.xml	Edgar Link	unprocessable
rgls-20190630_pre.xml	Edgar Link	unprocessable
rgls20190630-10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2019 Q3 Form 10-Q Financial Statement

#000162828019010478 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2019 Q3 Form 10-Q Financial Statement

#000162828019010478 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls